Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership

Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.

Proceeds from the financing will support the advancement of GelMEDIX’s lead cell therapy program, GMX-101, for the treatment of late-stage Geographic Atrophy, a progressive and irreversible form of macular degeneration, as well as the development of its next-generation hydrogel regenerative therapy platform.

The financing transaction was led by partner Kurt Machemer (Boston), along with counsel Maria Stracqualursi (Boston). Partner Greg Ikonen (San Francisco) led the collaboration agreement.

About Crowell & Moring

Crowell & Moring is an international law firm with operations in the United States, Europe, and MENA. Drawing on significant government, business, industry and legal experience, the firm helps clients capitalize on opportunities and provides creative solutions to complex litigation and arbitration, regulatory and policy, and corporate and transactional issues. The firm is consistently recognized for its commitment to pro bono service as well as its programs and initiatives to advance diversity, equity, and inclusion.